Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selexipag: A Review in Pulmonary Arterial Hypertension.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2016
Same author

Erratum to: Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2016
Same author

Trifluridine/Tipiracil: A Review in Metastatic Colorectal Cancer.

Drugs·2016
Same author

Etanercept (SB4): A Review in Autoimmune Inflammatory Diseases.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2016
Same author

Erratum to: Susoctocog Alfa: A Review in Acquired Haemophilia A.

Drugs·2016
Same author

Eltrombopag: A Review in Paediatric Chronic Immune Thrombocytopenia.

Drugs·2016

Related Experiment Video

Updated: Mar 28, 2026

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

10.2K

Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain.

Celeste B Burness1, Paul L McCormack2

  • 1Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. demail@springer.com.

Drugs
|December 16, 2015
PubMed
Summary

The capsaicin 8% patch effectively treats peripheral neuropathic pain, including painful diabetic peripheral neuropathy and postherpetic neuralgia. It offers sustained pain relief with an acceptable safety profile, showing comparable efficacy to pregabalin.

More Related Videos

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
07:12

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats

Published on: January 21, 2020

8.5K
Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx
06:05

Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx

Published on: May 2, 2025

1.2K

Related Experiment Videos

Last Updated: Mar 28, 2026

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

10.2K
Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats
07:12

Chronic Post-Ischemia Pain Model for Complex Regional Pain Syndrome Type-I in Rats

Published on: January 21, 2020

8.5K
Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx
06:05

Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx

Published on: May 2, 2025

1.2K

Area of Science:

  • Neurology
  • Dermatology
  • Pain Management

Background:

  • Peripheral neuropathic pain (PNP) is a debilitating condition with limited treatment options.
  • The capsaicin 8% patch (QUTENZA®) targets transient receptor potential vanilloid 1 channels to alleviate pain.

Purpose of the Study:

  • To evaluate the efficacy and safety of the capsaicin 8% patch in various peripheral neuropathic pain conditions.
  • To compare the capsaicin 8% patch with placebo, low-concentration capsaicin, and pregabalin.

Main Methods:

  • Multiple randomized controlled trials (RCTs) were conducted.
  • Participants received single or multiple 30-60 minute applications of the capsaicin 8% patch.
  • Pain scores, sleep quality, and adverse events were assessed.

Main Results:

  • Significant pain relief and improved sleep quality were observed in patients with painful diabetic peripheral neuropathy (PDPN).
  • Sustained pain relief was noted over 52 weeks with no neurological safety concerns.
  • The capsaicin 8% patch demonstrated non-inferiority to pregabalin in nondiabetic PNP and superior efficacy to low-concentration capsaicin in postherpetic neuralgia (PHN).
  • Results for HIV-associated neuropathy (HIV-AN) were equivocal.

Conclusions:

  • The capsaicin 8% patch is an effective treatment for various peripheral neuropathic pain conditions, including PDPN and PHN.
  • It offers sustained pain relief and a favorable safety profile, with transient application-site reactions being the most common adverse events.
  • The patch represents a valuable therapeutic option for managing neuropathic pain.